Double-Stapled Peptides for RSV Fusion Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for human respiratory syncytial virus (RSV) infections, particularly in infants and vulnerable populations, are limited due to the lack of effective vaccines and therapies, with existing antiviral compounds facing challenges such as poor potency and stability issues.
Innovation Solution
Development of novel short double-stapled peptides that are highly potent and stable against proteolytic degradation, specifically targeting the RSV fusion protein to inhibit viral entry into host cells, offering improved pharmaceutical use and formulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antiviral compounds are used for RSV treatment, then some therapeutic effect is achieved, but potency and stability are insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of HR2 peptides through stapling - introducing cyclic constraints at specific positions (i, i+3 or i, i+4) to alter the conformational parameters. This stabilizes the alpha-helical structure and resistance to proteolytic degradation while maintaining or enhancing antiviral potency against RSV
Solution Approach 2:
The invention creates composite peptide structures by combining stabilized HR2 sequences with specific stapling motifs. The double-stapled design integrates two cyclic constraints within the peptide backbone, forming a composite structure that simultaneously achieves enhanced stability and potency, represented by sequences like C1-C20 with staples at multiple positions
2Reliability
If longer peptide sequences are used to improve stability, then proteolytic resistance increases, but molecular weight and complexity increase
Solution Approach 1:
The patent segments the HR2 peptide sequence into specific regions for stapling modification. By introducing cyclic constraints at strategically selected positions within the 20-amino acid sequence, the peptide is divided into constrained segments that resist proteolytic cleavage, achieving high stability without requiring full-length extended sequences
Solution Approach 2:
The invention changes the structural parameters of the peptide by introducing cyclic staples that constrain the backbone conformation. This parameter modification increases proteolytic resistance by preventing enzyme access to cleavage sites, while maintaining a compact molecular weight of approximately 20 amino acids rather than requiring much longer sequences
3Quantity of substance
If HR2 peptides are stabilized through cross-linking to improve potency, then antiviral activity increases, but susceptibility to proteolytic degradation increases
Solution Approach 1:
The patent resolves this contradiction by changing the stapling parameters - using hydrocarbon staples that create cyclic constraints without introducing chemically reactive cross-linking groups. This approach stabilizes the alpha-helical conformation for high antiviral potency while the inert hydrocarbon nature of the staples prevents additional susceptibility to proteolytic degradation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These peptides demonstrate nanomolar potency and enhanced stability, providing a more effective prevention and treatment option for RSV infections, including lower respiratory infections, with improved safety and efficacy compared to previous compounds.
Implementation Method 1
The stapled peptides demonstrate nanomolar potency in HEp-2 cells and are exceptionally robust to degradation in the presence of proteolytic enzymes
Implementation Method 2
These peptides are two times shorter than T118, one of the best native peptide reported previously, but are 10-fold more potent inhibitors despite the significant difference in length
Data Source
AI summary
The present invention relates novel peptides useful for the prevention and/or treatment of respiratory syncytial virus (RSV) infections.